Radhia M’Kacher, Laurent Andréoletti, Stéphane Flamant, Fabien Milliat, T. Girinsky, Joseph Dossou, D. Violot, E. Assaf, Bernard Clausse, Serge Koscielny, Jean Bourhis, J. Bosq, Alain Bernheim, C Parmentier, Patrice Carde,
BackgroundB cells are potential sites for latency and reactivation of the human neurotropic JC polyomavirus (JCV). We investigated JCV and Epstein–Barr virus (EBV) status in peripheral blood lymphocytes (PBL) from 74 Hodgkin's lymphoma (HL) and 91 B-cell non-Hodgkin's lymphoma (B-NHL) patients.Patients and methodsJCV and EBV DNA were assessed by PCR, and FISH technique was used to localize viral infection and to estimate chromosomal instability (rogue cells, 'chromosomal aberrations') throughout evolution. ...
Tópico(s): Energy Harvesting in Wireless Networks
2009 - Elsevier BV | Annals of Oncology
Patrice Carde, Laurent Andréoletti, Serge Koscielny, E. Assaf, T. Girinsky, J. Bosq, Alain Bernheim, Stéphane Flamant, D. Violot, C Parmentier, Radhia M’Kacher,
7551 Background: The HRS derive from germinal-center B-cells, potential sites for latency and reactivation of JCV in immunosuppressed individuals. Replication of human polyomaviruses (JC, BK, SV40) and EBV was assessed in Hodgkin (HL) and B cell non-Hodgkin (B-NHL) lymphomas. Methods: FISH, immunohistochemistry for oncogenic proteins, PCR and DNA sequencing to identify polyomaviruses and EBV on involved nodes and in PBL before, during and after treatment (N = 73 HL, 91 B-NHL). Controls were 30 healthy ...
Tópico(s): Energy Harvesting in Wireless Networks
2006 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Roberto Ferrara, Laura Mezquita, Matthieu Texier, J. Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazières, Gérard Zalcman, Solenn Brosseau, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Corentin Lefebvre, R. Veillon, Virginie Westeel, Serge Koscielny, Stéphane Champiat, Charles Ferté, David Planchard, Jordi Remón, Marie‐Eve Boucher, Anas Gazzah, Julien Adam, Emilio Bria, Giampaolo Tortora, Jean‐Charles Soria, Benjamin Besse, Caroline Caramella,
Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown.To investigate whether HPD is observed in patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors compared with single-agent chemotherapy and whether there is an association between treatment and HPD.In this ...
Tópico(s): Lung Cancer Research Studies
2018 - American Medical Association | JAMA Oncology
Produção Nacional
Revisado por pares
Roberto Ferrara, Laura Mezquita, Matthieu Texier, J. Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazières, Gérard Zalcman, Solenn Brosseau, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Corentin Lefebvre, R. Veillon, Virginie Westeel, Serge Koscielny, Stéphane Champiat, Charles Ferté, David Planchard, Jordi Remón, Marie Eve Boucher, Anas Gazzah, Julien Adam, Giuseppe Lo Russo, Diego Signorelli, Marina Chiara Garassino, Jean Charles Soria, Caroline Caramella, Benjamin Besse,
Hyperprogressive disease (HPD), fast progression (FP), and early death (ED) have been described in 13.8%, 4.7%, and 5.6% and in 5.1%, 2.8%, and 6.8%, respectively, of patients with non-small-cell lung cancer (NSCLC) treated with single-agent programmed cell death ligand 1 inhibitors (ICI) or chemotherapy, respectively. Whether FP/ED and HPD represent overlapping patterns is unknown.FP, ED, and HPD were retrospectively assessed in patients with NSCLC treated with single-agent ICI or chemotherapy. Eligibility ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2020 - Lippincott Williams & Wilkins | JCO Precision Oncology
Paul Flicek, M Ridwan Amode, Daniel Barrell, Kathryn Beal, Shannon E. Brent, Denise Carvalho‐Silva, Peter Clapham, Guy Coates, Susan Fairley, Stephen Fitzgerald, Laurent Gil, Leo I. Gordon, Maurice Hendrix, Thibaut Hourlier, Nathan Johnson, Andreas Kähäri, D. Keefe, Stephen Keenan, Rhoda Kinsella, Monika Komorowska, Gautier Koscielny, Eugene Kulesha, Pontus Larsson, I. Longden, William McLaren, Matthieu Muffato, Bert Overduin, Miguel Pignatelli, Bethan Pritchard, Harpreet Singh Riat, Graham R. S. Ritchie, Magali Ruffier, Michael Schuster, Daniel Sobral, Amy Tang, Kieron Taylor, Stephen J. Trevanion, Jana Vandrovcová, Simon White, Mark H. Wilson, Steven P. Wilder, Bronwen Aken, Ewan Birney, Fiona Cunningham, Ian Dunham, Richard Durbin, Xosé M. Fernández, Jennifer Harrow, Javier Herrero, Tim Hubbard, Anne Parker, Glenn Proctor, Giulietta Spudich, Jan-Hinnerk Vogel, Andrew Yates, Amonida Zadissa, Stephen M. J. Searle,
The Ensembl project (http://www.ensembl.org) provides genome resources for chordate genomes with a particular focus on human genome data as well as data for key model organisms such as mouse, rat and zebrafish. Five additional species were added in the last year including gibbon (Nomascus leucogenys) and Tasmanian devil (Sarcophilus harrisii) bringing the total number of supported species to 61 as of Ensembl release 64 (September 2011). Of these, 55 species appear on the main Ensembl website and six ...
Tópico(s): Epigenetics and DNA Methylation
2011 - Oxford University Press | Nucleic Acids Research
Roberto Ferrara, Caroline Caramella, Matthieu Texier, Clarisse Audigier-Valette, Laurent Tessonnier, Laura Mezquita, J. Lahmar, Julien Mazières, Gérard Zalcman, Solenn Brosseau, Virginie Westeel, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, R. Veillon, David Planchard, Mathieu Boucher, Serge Koscielny, J.C. Soria, Benjamin Besse,
Background: Using Tumor Growth Rate (TGR), we previously described HPD in 10% of 89 NSCLC pts treated with IO in a single institution. In this retrospective study, we explored HPD in a larger and multicenter cohort of advanced NSCLC pts treated with IO. Methods: We performed a clinical and radiological retrospective analysis of consecutive NSCLC pts, treated with IO, in 5 different institutions, between November 2012 and March 2017. Eligibility criteria required, for each patient, 3 CT scans performed ...
Tópico(s): Lung Cancer Research Studies
2017 - Elsevier BV | Annals of Oncology
Hadrien D’inca, Julien Namur, S. Ghegediban, Michel Wassef, Florentina Pascale, Alexandre Laurent, Michel Manfait,
... humans,6Ramirez L.H. Juliéron M. Bonnay M. Koscielny S. Zhao Z. Gouyette A. Munck J.N. ...
Tópico(s): Infrared Thermography in Medicine
2015 - Elsevier BV | American Journal Of Pathology
Vincent Ribrag, Serge Koscielny, Olivier Casasnovas, Cécile Cazeneuve, Pauline Brice, Franck Morschhauser, Jean Gabarre, Marine Diviné, Laurent Voillat, Apasia Stamatoullas, Gilbert Lenoir, Gilles Salles,
Abstract Hodgkin lymphoma is a highly curable malignancy, but treatment outcome might be influenced by some patient’s germline polymorphisms that determine anticancer agent metabolism. We prospectively collected peripheral blood lymphocytes from 313 patients with Hodgkin lymphomas in order to analyze GSTP1, GSTM1, GSTT1, UGT1A1 and CYP 450-3A4 genes polymorphisms. Median age was 32 year (range 15 – 93), 60% of the patients were treated for a stage I/II (localized) Hodgkin’s lymphomas. Median follow- ...
Tópico(s): Lung Cancer Treatments and Mutations
2006 - Elsevier BV | Blood